Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
Healthcare
$5.32 +0.56%
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
52W Low $4.35High $9.57
Volume 1.39M
Average 1.82M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$48.27M
FY 2025 · Annual
Net Income
-$38.18M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 125K | 125K | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 125K | 125K | 0 | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 15.18M | 20.79M | 24.51M | 19.31M | 30.5M |
| Selling, General & Admin | 10.67M | 14.06M | 13.89M | 14.06M | 17.77M |
| Operating Expenses | 24.78M | 34.8M | 38.39M | 33.37M | 48.27M |
| Depreciation & Amortization | 232K | 778K | 960K | 990K | 845K |
| EBITDA | (24.42M) | (16.31M) | (34.38M) | (52.1M) | (35.22M) |
| EBITDA Margin | -19534.4% | -13046.4% | — | — | — |
| Operating Income | (24.65M) | (34.67M) | (38.39M) | (33.37M) | (48.27M) |
| Operating Margin | -19720.0% | -27739.2% | — | — | — |
| Interest Income | 0 | 1.22M | 2.08M | 1.09M | 3.92M |
| Interest Expense | 53K | 1.71M | 2.6M | 2.09M | 2.12M |
| Other Income / Expenses | (10.4M) | 15.93M | 452K | (21.81M) | 10.08M |
| Income Before Tax | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Pre-Tax Margin | -28899.2% | -15035.2% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Net Margin | -28899.2% | -15035.2% | — | — | — |
| EPS (Basic) | (1.26) | (0.10) | (1.31) | (1.74) | (0.72) |
| EPS (Diluted) | (1.26) | (0.10) | (1.31) | (1.74) | (0.72) |
| 28.69M | 28.82M | 28.94M | 31.68M | 52.96M | |
| 28.69M | 28.82M | 28.94M | 31.68M | 52.96M |
CADL Earnings Waterfall · TTM
NASDAQ:CADL · Revenue to Net Income
Key Ratios
EPS$-0.98
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-7.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$54.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.98, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 424B5 | 424B5 filing | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 |
How much revenue does CADL generate?
Candel Therapeutics, Inc. (CADL) reported $0.00 of revenue in fiscal 2025.
Is CADL profitable?
Candel Therapeutics, Inc. (CADL) reported -$38.18M of net income.
Continue the stock analysis
Jump to another research area for this company.